Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro - Top-Institutions - MDSpire

Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro

  • By

  • Manoj S Nair

  • Maria I Luck

  • Yaoxing Huang

  • Yosef Sabo

  • David D Ho

  • August 12, 2024

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Virology
    • Immunology

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Virology
    • Clinical Research

  • #3

    University of Washington School of Medicine
    University of Washington School of Medicine

    Seattle, WA

    Key Differentiators

    • Virology
    • Infectious Diseases
    • Pharmacology

  • #4

    Massachusetts General Hospital, Harvard Medical School
    Massachusetts General Hospital, Harvard Medical School

    Boston, MA

    Key Differentiators

    • Infectious Diseases
    • Virology
    • Clinical Pharmacology

  • #5

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Virology
    • Immunology
    • Infectious Diseases

Original Source(s)

Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro

  • by Manoj S Nair, Maria I Luck, Yaoxing Huang, Yosef Sabo, David D Ho

  • August 12, 2024

Related Content

Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis

Clinical characteristics and antibody responses to Omicron variants among pregnant women in China during the December 2022–April 2023 COVID-19 pandemic wave

Effectiveness of Telemedicine vs Face-to-Face Consultation in Fighting COVID-19: Retrospective Cohort Study of Adult Patients With COVID-19 in a Primary Care Setting